

# EuroGuiDerm guideline for the systemic treatment of psoriasis vulgaris.

Guideline ID: 2156

Published: 2025 Feb

## EuroGuiDerm Centre for Guideline Development

*Nast A, Spuls PI, Dressler C, et al. EuroGuiDerm guideline for the systemic treatment of psoriasis vulgaris. Zurich (Switzerland): European Dermatology Forum (EDF); 2025 Feb. 234 p. [465 references]*

[View Original Guideline](#)

## Overview

## Guideline Objective

To provide guidance for optimal treatment selection and management in the treatment of adults with moderate-to-severe plaque-type psoriasis

## Patient Population

Adult patients with plaque-type psoriasis of moderate-to-severe severity, and patients with psoriatic arthritis, who have also been diagnosed with moderate-to-severe psoriasis vulgaris

## Recommendations

## Recommendation Statements

Major interventions covered in this guideline include:

- Factors for consideration when initiating and selecting systemic treatment
- Choice of first line and subsequent agents
- Considerations for use of specific agents

**Note:** Full recommendation statements have not been provided because this guideline does not meet [EGT's systematic review of the evidence criteria](#). Refer to the [original guideline](#) for more information.

## Evidence Rating Scheme

Refer to the original guideline documentation for more information.

## Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

### Related Content

## Supporting Documents

- [Living Version of Full Guideline](#); 2025 Feb.
- [Methods & Evidence Report](#); 2025 Feb.
- [Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: a Network Meta-analysis](#); 2022 May 23.
- [EuroGuiDerm Guideline and Consensus Statement Development Manual. Version 1.3](#); 2020 Feb.

## Implementation Tools

- [Implementation Slides](#); 2025 Feb.

- [EDF Guidelines App](#).

## Patient Education

- [A Patient Guide to Using The EuroGuiDerm Guideline for the Systemic Treatment of Psoriasis Vulgaris](#); 2023.

**Note:** This patient information is intended to help patients better understand their health and their diagnosed disorders. Patients and their representatives should still consult with a licensed health care professional for evaluation of treatment options as well as answers to their personal medical questions.

### Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.